药物洗脱支架：成本与临床效益对比 - Suppr

Suppr

超能文献

Drug-eluting stents: cost versus clinical benefit.

作者信息

Lemos Pedro A, Serruys Patrick W, Sousa J Eduardo

机构信息

Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.

出版信息

Circulation. 2003 Jun 24;107(24):3003-7. doi: 10.1161/01.CIR.0000078025.19258.28.

DOI:10.1161/01.CIR.0000078025.19258.28

PMID:12821586

Abstract

摘要

相似文献

Drug-eluting stents: cost versus clinical benefit.

Circulation. 2003 Jun 24;107(24):3003-7. doi: 10.1161/01.CIR.0000078025.19258.28.

Drug-eluting stents: costs versus clinical benefit.

Circulation. 2003 Jun 24;107(24):3008-11. doi: 10.1161/01.CIR.0000079018.84618.0E.

Drug-eluting stents: new era and new concerns.

Postgrad Med J. 2004 Jan;80(939):13-8. doi: 10.1136/pmj.2003.009431.

Coronary brachytherapy in the drug-eluting stent era: don't bury it alive.

Circulation. 2003 Jul 29;108(4):386-8. doi: 10.1161/01.CIR.0000082928.33891.B7.

Hippocrates revisited: the evidence for drug-eluting stents.

Circulation. 2003 Jun 24;107(24):3012-4. doi: 10.1161/01.CIR.0000079940.15982.75.

Lack of efficacy and cost-effectiveness of drug-eluting stents.

Eur Heart J. 2006 Dec;27(24):3075-6; author reply 3076. doi: 10.1093/eurheartj/ehl408. Epub 2006 Nov 24.

Drug eluting stents: maximising benefit and minimising cost.

Heart. 2003 Feb;89(2):127-31. doi: 10.1136/heart.89.2.127.

Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents.

Can J Cardiol. 2005 Jul;21(9):783-7.

Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials.

Circulation. 2005 Nov 1;112(18):2833-9. doi: 10.1161/CIRCULATIONAHA105.570093.

Are drug eluting stents really worth the money?

Heart. 2006 Jan;92(1):5-7. doi: 10.1136/hrt.2005.066316. Epub 2005 Jun 6.

引用本文的文献

A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease.

Heart Int. 2019 Dec 23;13(2):17-24. doi: 10.17925/HI.2019.13.2.17. eCollection 2019.

A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells.

Sci Rep. 2018 Nov 8;8(1):16551. doi: 10.1038/s41598-018-34877-8.

3D Printed Antibiotic and Chemotherapeutic Eluting Catheters for Potential Use in Interventional Radiology: In Vitro Proof of Concept Study.

Acad Radiol. 2019 Feb;26(2):270-274. doi: 10.1016/j.acra.2018.03.022. Epub 2018 May 22.

Predictors of major adverse cardiac events following elective stenting of large coronary arteries.

Indian Heart J. 2018 Jan-Feb;70(1):20-23. doi: 10.1016/j.ihj.2017.06.011. Epub 2017 Jun 19.

Enhanced biocompatibility of CD47-functionalized vascular stents.

Biomaterials. 2016 May;87:82-92. doi: 10.1016/j.biomaterials.2016.02.008. Epub 2016 Feb 8.

Surface Modification of Biodegradable Polymers towards Better Biocompatibility and Lower Thrombogenicity.

PLoS One. 2015 Dec 7;10(12):e0142075. doi: 10.1371/journal.pone.0142075. eCollection 2015.

Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India.

Indian Heart J. 2013 Sep-Oct;65(5):586-92. doi: 10.1016/j.ihj.2013.08.030. Epub 2013 Sep 21.

Perioperative management of antiplatelet therapy in patients with drug-eluting stents.

HSR Proc Intensive Care Cardiovasc Anesth. 2012;4(3):153-67.

Gene delivery technologies for cardiac applications.

Gene Ther. 2012 Jun;19(6):659-69. doi: 10.1038/gt.2012.11. Epub 2012 Mar 15.

Luminal flow amplifies stent-based drug deposition in arterial bifurcations.

PLoS One. 2009 Dec 2;4(12):e8105. doi: 10.1371/journal.pone.0008105.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Drug-eluting stents: cost versus clinical benefit.

作者信息

Lemos Pedro A, Serruys Patrick W, Sousa J Eduardo

机构信息

Thoraxcenter, Erasmus Medical Center, Rotterdam, Netherlands.

出版信息

Circulation. 2003 Jun 24;107(24):3003-7. doi: 10.1161/01.CIR.0000078025.19258.28.

DOI:10.1161/01.CIR.0000078025.19258.28

PMID:12821586

Abstract

摘要

相似文献

Drug-eluting stents: cost versus clinical benefit.

Circulation. 2003 Jun 24;107(24):3003-7. doi: 10.1161/01.CIR.0000078025.19258.28.

Drug-eluting stents: costs versus clinical benefit.

Circulation. 2003 Jun 24;107(24):3008-11. doi: 10.1161/01.CIR.0000079018.84618.0E.

Drug-eluting stents: new era and new concerns.

Postgrad Med J. 2004 Jan;80(939):13-8. doi: 10.1136/pmj.2003.009431.

Coronary brachytherapy in the drug-eluting stent era: don't bury it alive.

Circulation. 2003 Jul 29;108(4):386-8. doi: 10.1161/01.CIR.0000082928.33891.B7.

Hippocrates revisited: the evidence for drug-eluting stents.

Circulation. 2003 Jun 24;107(24):3012-4. doi: 10.1161/01.CIR.0000079940.15982.75.

Lack of efficacy and cost-effectiveness of drug-eluting stents.

Eur Heart J. 2006 Dec;27(24):3075-6; author reply 3076. doi: 10.1093/eurheartj/ehl408. Epub 2006 Nov 24.

Drug eluting stents: maximising benefit and minimising cost.

Heart. 2003 Feb;89(2):127-31. doi: 10.1136/heart.89.2.127.

Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents.

Can J Cardiol. 2005 Jul;21(9):783-7.

Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials.

Circulation. 2005 Nov 1;112(18):2833-9. doi: 10.1161/CIRCULATIONAHA105.570093.

Are drug eluting stents really worth the money?

Heart. 2006 Jan;92(1):5-7. doi: 10.1136/hrt.2005.066316. Epub 2005 Jun 6.

引用本文的文献

A Review of the Ultrathin Orsiro Biodegradable Polymer Drug-eluting Stent in the Treatment of Coronary Artery Disease.

Heart Int. 2019 Dec 23;13(2):17-24. doi: 10.17925/HI.2019.13.2.17. eCollection 2019.

A rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells.

Sci Rep. 2018 Nov 8;8(1):16551. doi: 10.1038/s41598-018-34877-8.

3D Printed Antibiotic and Chemotherapeutic Eluting Catheters for Potential Use in Interventional Radiology: In Vitro Proof of Concept Study.

Acad Radiol. 2019 Feb;26(2):270-274. doi: 10.1016/j.acra.2018.03.022. Epub 2018 May 22.

Predictors of major adverse cardiac events following elective stenting of large coronary arteries.

Indian Heart J. 2018 Jan-Feb;70(1):20-23. doi: 10.1016/j.ihj.2017.06.011. Epub 2017 Jun 19.

Enhanced biocompatibility of CD47-functionalized vascular stents.

Biomaterials. 2016 May;87:82-92. doi: 10.1016/j.biomaterials.2016.02.008. Epub 2016 Feb 8.

Surface Modification of Biodegradable Polymers towards Better Biocompatibility and Lower Thrombogenicity.

PLoS One. 2015 Dec 7;10(12):e0142075. doi: 10.1371/journal.pone.0142075. eCollection 2015.

Clinical outcomes with Biolimus (A9)™ eluting stent, 'BioMatrix' in diabetic patients--interim results from multicenter post market surveillance registry in India.

Indian Heart J. 2013 Sep-Oct;65(5):586-92. doi: 10.1016/j.ihj.2013.08.030. Epub 2013 Sep 21.

Perioperative management of antiplatelet therapy in patients with drug-eluting stents.

HSR Proc Intensive Care Cardiovasc Anesth. 2012;4(3):153-67.

Gene delivery technologies for cardiac applications.

Gene Ther. 2012 Jun;19(6):659-69. doi: 10.1038/gt.2012.11. Epub 2012 Mar 15.

Luminal flow amplifies stent-based drug deposition in arterial bifurcations.

PLoS One. 2009 Dec 2;4(12):e8105. doi: 10.1371/journal.pone.0008105.